[Annonce événementielle au sens de l’art. 53 RC] Roche fait état d’une bonne croissance de ses ventes malgré une baisse de la demande de produits liés au COVID-19
October 19, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Bâle, le 19 octobre 2023 Les ventes du groupe ont augmenté de 1 %1 à taux de change constants (TCC) au cours des neuf premiers mois, avec une forte augmentation de 7 % au troisième trimestreSans les...
Late-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
October 13, 2023 09:30 ET
|
F. Hoffmann-La Roche Ltd
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to...
New data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
October 12, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
10-year efficacy data highlight OCREVUS’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from...
Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
October 11, 2023 02:00 ET
|
F. Hoffmann-La Roche Ltd
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeks OCREVUS subcutaneous injection was comparable to...
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
October 02, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS...
Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?
August 01, 2023 12:02 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis (RMS) market continues to offer drug...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet starkes Wachstum im Basisgeschäft beider Divisionen; Konzernverkäufe und -gewinn widerspiegeln rückläufige Nachfrage nach COVID-19-Produkten
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 27. Juli 2023 Verkäufe der Roche-Gruppe ohne COVID-19-Produkte steigen deutlich um 8%1 zu konstanten Wechselkursen (CER) Durch die erwartungsgemäss rückläufige Nachfrage nach...
[Annonce événementielle au sens de l’art. 53 RC] Roche fait état d’une forte croissance de son activité de base dans ses deux divisions ; les ventes et le bénéfice du groupe reflètent la baisse des ventes de produits liés au COVID-19
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Bâle, le 27 juillet 2023 Sans les produits liés au COVID-19, le chiffre d’affaires consolidé a fortement augmenté de 8 %1 à taux de change constants (TCC) Conformément à la baisse de la demande...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 27 July 2023 Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER) In line with the expected declining demand for COVID-19 products, Group sales...
Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
July 13, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS...